Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 293
Titolo Data di pubblicazione Autore(i) File
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 1-gen-2025 Manfredi, Giulia Francesca; Fulgenzi, Claudia Angela Maria; Celsa, Ciro; Stefanini, Bernardo; D'Alessio, Antonio; Pinter, Matthias; Scheiner, Bernhard; Awosika, Nichola; Brunetti, Leonardo; Lombardi, Pasquale; Latchford, Charles; Lee, Pei-Chang; Huang, Yi-Hsiang; Lin, Chun-Yen; Dalbeni, Andrea; Vogel, Arndt; Galle, Peter R.; Kudo, Masatoshi; Rimassa, Lorenza; Chon, Hong Jae; Cabibbo, Giuseppe; Piscaglia, Fabio; Cammà, Calogero; Pillai, Anjana; Pirisi, Mario; Singal, Amit G.; Pinato, David J.
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 1-gen-2025 Lombardi, Pasquale; Kim, Jung Sun; Manfredi, Giulia F.; Celsa, Ciro; Fulgenzi, Claudia A. M.; D'Alessio, Antonio; Stefanini, Bernardo; Doshi, Niraj C.; Warmington, Emily; Marron, Thomas U.; Pinter, Matthias; Scheiner, Bernhard; Kang, Beodeul; Lim, Ho Yeong; Hsu, Wei-Fan; Wietharn, Brooke; Silletta, Marianna; Parisi, Alessandro; Lin, Chun-Yen; Dalbeni, Andrea; Masi, Gianluca; Schönlein, Martin; Von Felden, Johann; Piscaglia, Fabio; Galle, Peter R.; Kudo, Masatoshi; Pressiani, Tiziana; Rimassa, Lorenza; Pirisi, Mario; Cabibbo, Giuseppe; Chon, Hong Jae; Pinato, David J.
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 1-gen-2025 Celsa, Ciro; Di Maria, Gabriele; Lombardi, Pasquale; D'Alessio, Antonio; Fulgenzi, Claudia A M; Brunetti, Leonardo; Manfredi, Giulia F; Stefanini, Bernardo; Sparacino, Alba; Rigamonti, Cristina; Pirisi, Mario; Latchford, Charles; Vaccaro, Marco; Enea, Marco; Cammà, Calogero; Cabibbo, Giuseppe; Pinato, David James
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial 1-gen-2025 Takada, K.; Takamori, S.; Shimokawa, M.; Pinato, D. J.; Cortellini, A.
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer 1-gen-2025 Pinato, David J; Lombardi, Pasquale; D'Alessio, Antonio; Torkpour, Aria; Fulgenzi, Claudia Angela Maria; Brunetti, Leonardo
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer 1-gen-2024 Rakaee, Mehrdad; Tafavvoghi, Masoud; Ricciuti, Biagio; Alessi, Joao V; Cortellini, Alessio; Citarella, Fabrizio; Nibid, Lorenzo; Perrone, Giuseppe; Adib, Elio; Fulgenzi, Claudia A M; Murilo Hidalgo Filho, Cassio; Di Federico, Alessandro; Jabar, Falah; Hashemi, Sayed; Houda, Ilias; Richardsen, Elin; Rasmussen Busund, Lill-Tove; Donnem, Tom; Bahce, Idris; Pinato, David J; Helland, Åslaug; Sholl, Lynette M; Awad, Mark M; Kwiatkowski, David J
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 1-gen-2024 Korolewicz, James Alexander; Scheiner, Bernhard; Fulgenzi, Claudia A M; D'Alessio, Antonio; Cortellini, Alessio; Pascual, Chynna; Mehan, Aman; Partridge, Sarah; Gujral, Dorothy M; Mohammed, Waleed; Mohammed, Oreoluwa; Grzesiak, Aneta; Booker, Lauren; Cleator, Susan; Pokrovska, Tzveta; Saleem, Waqar; Rackie, James; Needham, Yasmine; Krell, Jonathan; Mcneish, Iain; Tookman, Laura; Park, Won-Ho Edward; Asif, Muzamil; Evans, Joanne S; Pinato, David J
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 1-gen-2024 Pinato, D. J.; D'Alessio, A.; Fulgenzi, C. A. M.; Schlaak, A. E.; Celsa, C.; Killmer, S.; Blanco, J. M.; Ward, C.; Stikas, C. -V.; Openshaw, M. R.; Acuti, N.; Nteliopoulos, G.; Balcells, C.; Keun, H. C.; Goldin, R. D.; Ross, P. J.; Cortellini, A.; Thomas, R.; Young, A. -M.; Danckert, N.; Tait, P.; Marchesi, J. R.; Bengsch, B.; Sharma, R.
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry 1-gen-2024 Vincenzi, Bruno; Cortellini, Alessio; Mazzocca, Alessandro; Orlando, Sarah; Romandini, Davide; Aguilar-Company, Juan; Ruiz-Camps, Isabel; Valverde Morales, Claudia; Eremiev-Eremiev, Simeon; Tondini, Carlo; Brunet, Joan; Bertulli, Rossella; Provenzano, Salvatore; Bower, Mark; Generali, Daniele; Salazar, Ramon; Sureda, Anna; Prat, Aleix; Vasiliki, Michalarea; Van Hemelrijck, Mieke; Sita-Lumsden, Ailsa; Bertuzzi, Alexia; Rossi, Sabrina; Jackson, Amanda; Grosso, Federica; Lee, Alvin J. X.; Murphy, Cian; Belessiotis, Katherine; Mukherjee, Uma; Pommeret, Fanny; Loizidou, Angela; Gaidano, Gianluca; Dettorre, Gino M.; Grisanti, Salvatore; Tucci, Marco; Fulgenzi, Claudia A. M.; Gennari, Alessandra; Napolitano, Andrea; Pinato, David J.
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 1-gen-2024 Luke, J. J.; Davar, D.; Andtbacka, R. H.; Bhardwaj, N.; Brody, J. D.; Chesney, J.; Coffin, R.; de Baere, T.; de Gruijl, T. D.; Fury, M.; Goldmacher, G.; Harrington, K. J.; Kaufman, H.; Kelly, C. M.; Khilnani, A. D.; Liu, K.; Loi, S.; Long, G. V.; Melero, I.; Middleton, M.; Neyns, B.; Pinato, D. J.; Sheth, R. A.; Solomon, S. B.; Szapary, P.; Marabelle, A.
Precision Targeting of the Gut Microbiome for Cancer Immunotherapy 1-gen-2024 Lombardi, P.; Pinato, D. J.
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 1-gen-2024 Mostaghim, Anahita; Minkove, Samuel; Aguilar-Company, Juan; Ruiz-Camps, Isabel; Eremiev-Eremiev, Simeon; Dettorre, Gino M.; Fox, Laura; Tondini, Carlo; Brunet, Joan; Carmona-García, Mcarmen; Lambertini, Matteo; Bower, Mark; Newsom-Davis, Thomas; Sharkey, Rachel; Dalla Pria, Alessia; Rossi, Maura; Plaja, Andrea; Salazar, Ramon; Sureda, Anna; Prat, Aleix; Michalarea, Vasiliki; Van Hemelrijck, Mieke; Sita-Lumsden, Ailsa; Bertuzzi, Alexia; Rimassa, Lorenza; Rossi, Sabrina; Paolo Pedrazzoli, Gianpiero Rizzo.; JX Lee, Alvin; Murphy, Cian; Belessiotis, Katherine; Diamantis, Nikolaos; Mukherjee, Uma; Pommeret, Fanny; Stoclin, Annabelle; Martinez-Vila, Clara; Bruna, Riccardo; Gaidano, Gianluca; D'Avanzo, Francesca; Gennari, Alessandra; Athale, Janhavi; Eichacker, Peter; Pinato, David J.; Torabi-Parizi, Parizad; Cortellini, Alessio
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 1-gen-2024 Celsa, Ciro; Cabibbo, Giuseppe; Pinato, David James
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 1-gen-2024 Smirne, Carlo; Crobu, Maria Grazia; Landi, Irene; Vercellino, Nicole; Apostolo, Daria; Pinato, David James; Vincenzi, Federica; Minisini, Rosalba; Tonello, Stelvio; D'Onghia, Davide; Ottobrelli, Antonio; Martini, Silvia; Bracco, Christian; Fenoglio, Luigi Maria; Campanini, Mauro; Berton, Alessandro Maria; Ciancio, Alessia; Pirisi, Mario
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 1-gen-2024 Cabibbo, Giuseppe; Celsa, Ciro; Battaglia, Salvatore; Enea, Marco; Di Maria, Gabriele; Grova, Alessandro; Ciccia, Roberta; Manfredi, Giulia F; Iavarone, Massimo; Vogel, Arndt; Singal, Amit G; Reig, Maria; Pinato, David J; Cammà, Calogero
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future 1-gen-2024 Singal, A. G.; Yarchoan, M.; Yopp, A.; Sapisochin, G.; Pinato, D. J.; Pillai, A.
Immunotherapy at all stages of hepatocellular carcinoma 1-gen-2024 Pinato, D. J.; Fulgenzi, C. A. M.; D'Alessio, A.
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer 1-gen-2024 Hedayat, S.; Cascione, L.; Cunningham, D.; Schirripa, M.; Lampis, A.; Hahne, J. C.; Tunariu, N.; Hong, S. P.; Marchetti, S.; Khan, K.; Fontana, E.; Angerilli, V.; Delrieux, M.; Rodrigues, D. N.; Procaccio, L.; Rao, S.; Watkins, D.; Starling, N.; Chau, I.; Braconi, C.; Fotiadis, N.; Begum, R.; Guppy, N.; Howell, L.; Valenti, M.; Cribbes, S.; Kolozsvari, B.; Kirkin, V.; Lonardi, S.; Ghidini, M.; Passalacqua, R.; Elghadi, R.; Magnani, L.; Pinato, D. J.; Di Maggio, F.; Ghelardi, F.; Sottotetti, E.; Vetere, G.; Ciraci, P.; Vlachogiannis, G.; Pietrantonio, F.; Cremolini, C.; Cortellini, A.; Loupakis, F.; Fassan, M.; Valeri, N.
Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival 1-gen-2024 Yang, L.; Murthy, S.; Cortellini, A.; Lim, E. A.; Gonzalez, M.; Pinato, D. J.; Abdel-Malek, M.; Mahmoud, S.; Martin, N. M.
Beyond Time and Space: Charting Dynamic Evolution of Sporadic Colorectal Cancer 1-gen-2024 Lombardi, P.; Pinato, D. J.
Mostrati risultati da 1 a 20 di 293
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile